ERBB2 and neoplasm: Interestingly, superior (and more rapid) tumor regression was achieved by dual FASN and HER2 blockade (87.2 ± 38.2 mm3; p-valuevsEGCG: 0. 017 and p-valuevsPertu: 0. 010), compared with EGCG or pertuzumab as single agents (Fig 4A, left panel).